GE pushes Hexvix technology to the fore in focus on bladder cancer
This article was originally published in Clinica
In a bid to capitalise on a largely untapped opportunity within the bladder cancer market, GE Healthcare (Chalfont St Giles, UK) is driving forward the global commercialisation of its Hexvix (hexaminolevulinate) fluorescence cystoscopy technology.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.